Form 4: Director Arno Acquires Options in Catheter Precision (VTAK)

Director Andrew Arno acquired options to purchase 50,000 shares of Catheter Precision, Inc. common stock.

Summary

• Director Andrew Arno acquired options to buy 50,000 shares of Catheter Precision, Inc. (VTAK) common stock on August 12, 2025.
• The exercise price of the options is $0.18 per share.
• The options vest in three equal annual installments starting one year from the grant date.
• The options expire on August 12, 2035.
• Following the transaction, Arno directly owns 50,000 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard disclosure of insider transactions.

Positives

• Director's acquisition of options may signal confidence in the company's future prospects.

Future Outlook

The filing does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Comparison to Industry Standards

• Option grants to directors are a common form of compensation in publicly traded companies, used to align their interests with shareholders.
• The vesting schedule of 1/3 per year is a standard vesting schedule.
• Comparable companies include medical device companies such as Medtronic, Boston Scientific, and Abbott, which also grant stock options to their directors and executives.

Stakeholder Impact

• Shareholders: The transaction provides information about insider activity, which can influence investor sentiment.
• Employees: No direct impact on employees.
• Customers: No direct impact on customers.
• Suppliers: No direct impact on suppliers.
• Creditors: No direct impact on creditors.

Key Dates

Keywords

options, Form 4, VTAK, Catheter Precision, director, Andrew Arno, beneficial ownership, insider trading